3 East 28th Street
10th Floor
New York, NY 10016
United States
332 206 0935
https://www.odonate.com
Secteur(s): Financial Services
Secteur d’activité: Shell Companies
Employés à temps plein: 137
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Kevin C. Tang | Chairman & CEO | 1 | S.O. | 1967 |
Mr. Michael S. Hearne | CFO & Principal Accounting Officer | 251,23k | S.O. | 1963 |
Mr. Ryan Cole | Senior Vice President of Operations | S.O. | S.O. | S.O. |
Dr. Steven S. Pfeiffer Ph.D. | Senior Vice President of Technical Operations | S.O. | S.O. | 1976 |
Mr. Thomas Wei | Chief Scientific Officer | S.O. | S.O. | 1976 |
Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New York.
L’ISS Governance QualityScore de Odonate, Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..